Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 6/20 | 0.46 |
| ▸ | NOS1 | P29475 | 5/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12516811 | 0.85 | KMT2A (0.50) | KMT2ABLMALOX15PMP22NOS2 | |
| SCHEMBL13410449 | 0.81 | GSR (0.52) | KMT2ABLMALOX15PMP22NOS2 | |
| SCHEMBL10187368 | 0.81 | GSR (0.52) | KMT2ABLMALOX15PMP22NOS2 | |
| SCHEMBL827027 | 0.80 | GSR (0.52) | KMT2ABLMALOX15PMP22NOS2 | |
| SCHEMBL12435528 | 0.77 | GSR (0.48) | KMT2ABLMALOX15PMP22NOS2 | |
| SCHEMBL10187392 | 0.77 | GSR (0.56) | KMT2ABLMALOX15PMP22NOS2 | |
| SCHEMBL26747924 | 0.77 | GSR (0.56) | KMT2ABLMALOX15PMP22NOS2 | |
| SCHEMBL3870750 | 0.77 | GSR (0.56) | KMT2ABLMALOX15PMP22NOS2 | |
| SCHEMBL10279976 | 0.77 | GSR (0.56) | KMT2ABLMALOX15PMP22NOS2 | |
| SCHEMBL261316 | 0.77 | GSR (0.56) | KMT2ABLMALOX15PMP22NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-9962450-B2 | Method of treating heart failure with modified relaxin polypeptides | AMBRX, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | AMBRX, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9567386-B2 | Therapeutic uses of modified relaxin polypeptides | AMBRX, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20120046229-A1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120041180-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110294161-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110288279-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110207914-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | AMBRX, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110124880-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110118451-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118501-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | APOB, APOL1, HDLBP | KMT2A 3808/4885BLM 3630/4885ALOX15 2322/4885 |
| US-20110288279-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | KMT2A 1481/4885BLM 3906/4885ALOX15 3334/4885 |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | KMT2A 1409/4885BLM 1698/4885ALOX15 1618/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | KMT2A 2012/4885BLM 4866/4885ALOX15 4277/4885 |
| US-20110118501-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | KMT2A 1481/4885BLM 3906/4885ALOX15 3334/4885 |
| US-20120041180-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | KMT2A 4789/4885BLM 3360/4885ALOX15 4101/4885 |
| US-20120046229-A1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | RXFP1, RXFP2, RXFP4 | KMT2A 4314/4885BLM 278/4885ALOX15 4607/4885 |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | FGF2, FGF1, FGF23 | KMT2A 3592/4885BLM 3753/4885ALOX15 4005/4885 |
| US-20110124880-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | KMT2A 1481/4885BLM 3906/4885ALOX15 3334/4885 |
| US-20110118451-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | KMT2A 1481/4885BLM 3906/4885ALOX15 3334/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | KMT2A 1152/4885BLM 2063/4885ALOX15 868/4885 |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | KMT2A 4314/4885BLM 278/4885ALOX15 4607/4885 |
| US-20110207914-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | KMT2A 4789/4885BLM 3360/4885ALOX15 4101/4885 |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | RXFP1, RXFP2, RXFP3 | KMT2A 2565/4885BLM 1527/4885ALOX15 3931/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | KMT2A 1890/4885BLM 4737/4885ALOX15 3690/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | KMT2A 2554/4885BLM 1433/4885ALOX15 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.